Aims Statin intolerance (SI) represents a significant public health problem for which precise
estimates of prevalence are needed. Statin intolerance remains an important clinical …

Abstract Treatment with statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A
reductase, has proven beneficial preventive effects on cardiovascular events. However …

Hyperlipidemia is a major risk factor for cardiovascular morbidity and mortality. Statins are
the first-choice therapy for dyslipidemias and are considered the cornerstone of …

The pharmacological treatment of dyslipidemia, a major modifiable risk factor for develo**
atherosclerotic cardiovascular disease (ASCVD), remains a debated and controversial …

Statin intolerance is a clinical syndrome whereby adverse effects (AEs) associated with
statin therapy [most commonly statin‐associated muscle symptoms (SAMS)] result in the …

Bempedoic acid is a new cholesterol-lowering drug, which has recently received US FDA
and EMA approval. This drug targets lipid and glucose metabolism as well as inflammation …

Background Despite the high incidence of patients with statin tolerance problems,
randomized evaluations of nonstatin oral treatment options for lowering of low-density …

Statins are the cornerstone of lipid-lowering therapies effective for cardiovascular risk
reduction. Although they are generally well tolerated, statin intolerance (SI) is frequent in …

Background Statin intolerance is associated with increased cardiovascular risk. Symptoms
and patients' characteristics are incompletely known. We aimed to analyse the health …

The modern history of cholesterol-lowering drugs started in 1972 when Dr. Akira Endo
identified an active compound (compactin) that inhibited cholesterol biosynthesis from the …